Connect Biopharma Holdings Limited Ordinary Shares
Veridion Score
Composite trend over time
Why is CNTB moving today?
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CNTB.
CNTB insider activity
Connect Biopharma Holdings Limited Ordinary Shares
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for CNTB.
CNTB contract awards, year to date.
Public federal awards linked to this ticker.
CNTB lobbying filings, year to date.
Registered lobbying filings matched to Connect Biopharma Holdings Limited Ordinary Shares.